Skip to main content

Perrin White, MD

Can you tell us a bit about the history of CAH—how it was discovered and what has shaped your lifelong interest in this condition, especially in the pediatric population?

Can you tell us a bit about the history of CAH—how it was discovered and what has shaped your lifelong interest in this condition, especially in the pediatric population?

Perrin White, MD

Can discuss the genetics of CAH—specifically, how specific alterations affect clinical presentation, the pathophysiology of CAH, and its therapeutic implications?

Can discuss the genetics of CAH—specifically, how specific alterations affect clinical presentation, the pathophysiology of CAH, and its therapeutic implications?

Perrin White, MD

Knowing the genetic underpinnings of the disease, how does this impact our current approach to CAH and suggest novel approaches for targeting specific pathways that drive the hypothalamic-pituitary-axis in CAH?

Knowing the genetic underpinnings of the disease, how does this impact our current approach to CAH and suggest novel approaches for targeting specific pathways that drive the hypothalamic-pituitary-axis in CAH?

Perrin White, MD

Once the diagnosis of 21-OH deficiency CAH has been established, what are the current therapeutic approaches at different times of life and, by extension, what are the unmet therapeutic needs?

Once the diagnosis of 21-OH deficiency CAH has been established, what are the current therapeutic approaches at different times of life and, by extension, what are the unmet therapeutic needs?

Perrin White, MD

How do the clinical end points and therapeutic concerns change as persons with CAH become adolescents and mature into early adulthood?

How do the clinical end points and therapeutic concerns change as persons with CAH become adolescents and mature into early adulthood?

Perrin White, MD

Although you have emphasized the current role of corticosteroid therapy in CAH, are there other adjunctive treatments that also play a role?

Although you have emphasized the current role of corticosteroid therapy in CAH, are there other adjunctive treatments that also play a role?

Perrin White, MD

What strategies are used to compensate for glucocorticoid-mediated side effects?

What strategies are used to compensate for glucocorticoid-mediated side effects?

Perrin White, MD

Can you discuss the problematic aspects of long-term corticosteroid treatment in CAH, including the challenges of delivering the right supra-physiologic doses of corticosteroid treatment?

Can you discuss the problematic aspects of long-term corticosteroid treatment in CAH, including the challenges of delivering the right supra-physiologic doses of corticosteroid treatment?

Perrin White, MD

What novel strategies—in particular, CRF receptor antagonism with crinecerfont—might be considered address the “therapeutic burden” associated with glucocorticoid therapy in CAH?

What novel strategies—in particular, CRF receptor antagonism with crinecerfont—might be considered address the “therapeutic burden” associated with glucocorticoid therapy in CAH?

Perrin White, MD

Based on the Phase 3 trial of crinecerfont in pediatric CAH—the CAHtalyst Trial—which patients are most likely suitable candidates for treatment with this novel therapey?

Based on the Phase 3 trial of crinecerfont in pediatric CAH—the CAHtalyst Trial—which patients are most likely suitable candidates for treatment with this novel therapey?

Perrin White, MD

What glucocorticoid dosing and/or biomarker metrics, such as 17-hydroxyprogesterone, might you consider when assessing suitability for CRF receptor antagonism with crinecerfont in the setting of CAH?

What glucocorticoid dosing and/or biomarker metrics, such as 17-hydroxyprogesterone, might you consider when assessing suitability for CRF receptor antagonism with crinecerfont in the setting of CAH?

Perrin White, MD

Although the CAHtalyst trials establish that you can improve 17-hydroxprogesterone and androstenedione levels while lowering the glucocorticoid dose, can we predict long-term benefits?

Although the CAHtalyst trials establish that you can improve 17-hydroxprogesterone and androstenedione levels while lowering the glucocorticoid dose, can we predict long-term benefits?

Perrin White, MD

How do we identify patients in late adolescence who might benefit from reductions in steroid dose? And who might be ideal candidates for CRF antagonists such as crinecerfont?

How do we identify patients in late adolescence who might benefit from reductions in steroid dose? And who might be ideal candidates for CRF antagonists such as crinecerfont?

Perrin White, MD

What should we look to in the future as far as our improved understanding of where and how CRF antagonists will fit into the therapeutic landscape for CAH?

What should we look to in the future as far as our improved understanding of where and how CRF antagonists will fit into the therapeutic landscape for CAH?

Perrin White, MD